Podcasts about substance use disorders

FILM FESTIVAL TICKETS: https://buytickets.at/thedopeyfoundation/2216905 PATREON: www.patreon.com/dopeypodcast Summary On this Dopey Monday Total Replay, Dave looks back at Dopey Episode 28, one of the strangest and creepiest early episodes of the show. It features Dave, Chris, and graphic-design Ryan — the guy who made the original Dopey logo — talking through old Lower East Side drug energy, the first major Dopey fan emails, weird ego stuff, drug stories, recovery, Rob Reiner, Nick Reiner, and a whole lot of eerie foreshadowing. Dave reflects on how painful it is to hear Chris again, knowing he died in 2018, and uses the episode to make a simple but brutal point: if Chris had stayed in recovery, he probably wouldn't have died. The replay itself is classic early Dopey: messy, funny, dark, uncomfortable, and weirdly prophetic. Ryan tells a story about refusing to leave a drug pickup even after a guy puts a gun to his head. Chris talks about addiction, genetics, rats drinking heroin water, and recovery. Dylan randomly calls in right as Dave is talking about Dylan from 90210, which feels like Dopey synchronicity. The episode also includes the first big fan email from Tina in Philadelphia, Dave getting wounded by being called “Dan,” and a long, now-haunting conversation about Rob Reiner and Nick Reiner before Nick ever appeared on Dopey. It's funny, painful, and very Dopey. PLUS Drugs, addiction and dumb shit on the new/old 10 year anniversary of this episode!(of Dopey)   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Emergency physicians pride themselves on recognizing and treating life-threatening illness under pressure. Yet one of the most lethal, common, and treatable conditions presenting to our EDs still often receives fragmented, stigmatized care: substance use disorder. The opioid crisis has evolved into an era of increasingly toxic and unpredictable drug supplies, including ultra-potent synthetic opioids such as nitazenes. Between 2016 and 2021, more than 27,000 Canadians died from opioid toxicity, while opioid-related ED visits continue to rise sharply. Patients discharged with untreated opioid use disorder face mortality rates approaching 5% within 12 months. Despite this, substance use disorder is still not consistently approached with the same urgency and systems-based care as other chronic high-risk illnesses. In this episode, Dr. Bjug Borgundvaag, Tish Mizon and Kari Herbert discuss how stigma affects care in the ED and how trauma-informed communication, person-first language, compassionate care, peer navigators and Bridge-style addiction programs can improve outcomes for both patients and clinicians. Please support EM Cases ongoing Free Open Access Medical Education learning platform with a donation here: https://emergencymedicinecases.com/donation/

This podcast is a brief review of emerging literature focusing on the potential use of GLP-1 receptor agonists in the treatment of mental health and substance use disorders. The episode explores how GLP-1 receptor agonists work to alter neurotransmitter systems and impact inflammation in the brain.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Last month we saw a big shift in the federal government's approach to psychedelic medicine.Specifically, following an executive order by President Trump, the FDA announced it is fast-tracking its review of several clinical trials of psychedelic drugs for patients with mental health disorders. The executive order also directed more funds towards psychedelic research and a review of psychedelics' status as highly restricted Schedule 1 substances. To help us understand what all this means for the future of psychedelic medicine and the neuroscience of psychedelics, we're joined by Boris Heifets, an anesthesiologist at Stanford Medicine who runs a lab studying how psychedelics affect the nervous system and their impact on patients with psychiatric conditions.Learn MoreThe Heifets Lab at Stanford MedicineFDA plans ultra-fast review of three psychedelic drugs following Trump directive (Associated Press, 2026)Trump's order on psychedelics could have far-reaching science consequences (Scientific American, 2026)Psychedelics, placebo, and anesthetic dreams (From Our Neurons to Yours, 2024)Pychedelics inside out — how do LSD and psilocybin alter perception? (From Our Neurons to Yours, 2024)The power of psychedelics meets the power of placebo (From Our Neurons to Yours, 2024)Magnesium–ibogaine therapy in veterans with traumatic brain injuries (Nature, 2024)Magnesium–ibogaine therapy effects on cortical oscillations and neural complexity in veterans with traumatic brain injury (Nature Mental Health, 2025)Send us a text!Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.We want to hear from your neurons! Email us at at neuronspodcast@stanford.eduLearn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn. 

Medicaid Managed Care Plan Alignment With State Substance Use Disorder Treatment Coverage Requirements The Milbank Quarterly Medicaid managed plan coverage for medications for alcohol use disorders (AUD) and opioid use disorder (OUD) varies across states but is generally lower in Republican-leaning states. Researchers conducted a national survey to evaluate if these differences in coverage were due to variation in state policy or variations in Medicaid managed plan alignment with state policy. Researchers found that while Republican-leaning states were generally a little less likely to require coverage of most or all medications for AUD and OUD and place limits on prior authorization, managed plans in Republican-leaning states were much less likely to follow state requirements. Given these findings, efforts to increase access to medications for AUD and OUD will need to address misalignment between managed care plans and state policy, and not just focus on making changes to state policy.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Dr. Eduardo Butelman (Icahn School of Medicine at Mount Sinai, New York) joins AJP Audio to discuss the varying incidence of psychiatric comorbidities across patients diagnosed with substance use disorders.  Afterwards, AJP Editor-in-Chief Dr. Ned Kalin joins the podcast to discuss the rest of the May issue, which includes a discussion on the future of the DSM. 00:53     Butelman interview 02:23     Mechanisms of difference between males and females 04:04     Patterns of response between males and females in substance use disorders 05:54     Implications for research into sex-based differences 07:33     Racial and ethnic variations in findings 09:30     Limitations 10:46     Immediate clinical implications? 12:09     Further research 13:18     Kalin interview 13:38     Butelman et al. 17:11     Hinojosa et al. 22:49     van Rooij et al. 26:06     The future of DSM Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse articles online. How authors may submit their work. Follow the journals of APA Publishing on Twitter. E-mail us at ajp@psych.org

On this episode of Health Talks, IPHCA's Behavioral Health/SUD Consultant, Stacy Agosto is joined by Dr. Kathleen McDonough and Dr. Mary Buswell from PCC Community Wellness Center who are both board certified in Family and Addiction Medicine. They share a wealth of knowledge on substance use disorders, including treatment and training.Dr. McDonough and Dr. Buswell's on demand training “Prescribing Buprenorphine: Putting Knowledge into Practice” can be found here: https://bit.ly/4cN0Omg

Join us as we review recent practice-changing articles on left atrial appendage closure vs AC for AFib, apixaban vs rivaroxaban for VTE, intensive LDL targeting, GLP1s and substance use disorders, and more! Fill your brain hole with a delicious stack of hotcakes! Featuring Paul Williams (@PaulNWilliamz), Shani Herzig (@ShaniHerzig) Rahul Ganatra (@rbganatra), and Matt Watto (@doctorwatto).Claim CME for this episode at curbsiders.vcuhealth.org!Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CMECredits Written and Hosted by: Rahul Ganatra MD, MPH; Shani Herzig, MD, MPH; Paul Williams, MD, FACP, Matthew Watto MD, FACP Cover Art: Rahul Ganatra MD, MPH Reviewer: Emi Okamoto, MD Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro, disclaimer Left atrial appendage closure vs anticoagulation in AF Apixaban vs rivaroxaban for VTE Intensive LDL targeting in ASCVD GLP1s and substance use disorders FDA approves Orforglipron E-cigarettes and cancer Early AM blood draws and sleep quality Outro Sponsor: FIGSGo to wearfigs.com to get 20% off during Nurses WeekSponsor: Panacea Financial If you're about to make the leap into  residency and feeling the financial pressure of that transition, visit PanaceaFinancial.com/curbsiders todaySponsor: MasterClass Right now, as a listener of this show, you get at least 15% off any annual membership at MASTERCLASS.com/CURB.